|Application ||WB, IHC, FC, E|
|Description||The protein encoded by this gene is a plasma membrane protein that catalyzes the conversion of extracellular nucleotides to membrane-permeable nucleosides. The encoded protein is used as a determinant of lymphocyte differentiation. Defects in this gene can lead to the calcification of joints and arteries. Two transcript variants encoding different isoforms have been found for this gene.|
|Immunogen||Purified recombinant fragment of human NT5E (AA: 30-250) expressed in E. Coli.|
|Formulation||Purified antibody in PBS with 0.05% sodium azide.|
|Other Names||5'-nucleotidase, 5'-NT, 18.104.22.168, Ecto-5'-nucleotidase, CD73, NT5E, NT5, NTE|
WB~~1/500 - 1/2000
FC~~1/200 - 1/400
IHC~~1/200 - 1/1000
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||NT5E Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. ; ;
1. Appl Immunohistochem Mol Morphol. 2012 Mar;20(2):103-7. 2. J Surg Oncol. 2012 Aug 1;106(2):130-7.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.